Actuate Therapeutics (NASDAQ:ACTU) Major Shareholder Leslie W. Kreis Sells 24,999 Shares of Stock

Actuate Therapeutics (NASDAQ:ACTU) major shareholder Leslie W. Kreis sold 24,999 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the sale, the insider now owns 131,248 shares in the company, valued at $1,181,232. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Actuate Therapeutics Trading Up 6.3 %

NASDAQ ACTU opened at $9.15 on Thursday. Actuate Therapeutics has a 1 year low of $7.50 and a 1 year high of $9.88.

About Actuate Therapeutics

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), an ATP competitive small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.